Oncotelic Therapeutics Featured in BioMedWire Editorial on CNS Drug Delivery Innovation

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced its placement in a BioMedWire editorial that examines emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial highlights Oncotelic's proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain. This positions the company within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications and other CNS-related conditions.

The blood-brain barrier has long been a formidable obstacle in treating neurological disorders, preventing many therapeutic agents from reaching the brain. Oncotelic's platform addresses this challenge by delivering drugs directly from the nasal cavity to the brain, bypassing the barrier. This innovation could have significant implications for conditions such as Alzheimer's disease, Parkinson's disease, brain tumors, and even chemical or biological threats where rapid brain access is critical.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes.

The editorial underscores the market potential for CNS drug delivery, as the global market for neurological therapeutics is expected to grow substantially. By enabling non-invasive delivery of drugs to the brain, Oncotelic's platform could reduce side effects and improve patient compliance compared to traditional methods like injections or implants.

In addition to its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates, further strengthening its position in oncology and rare disease therapeutics.

For more information, the full press release is available at https://ibn.fm/Y8E3U. The latest news and updates relating to the company can be found at https://ibn.fm/OTLC.